This trial is testing a new drug combo to treat various solid tumors and a type of lymphoma. They want to see if it's effective and safe, and also figure out the best way to give the drugs.
1 Primary · 15 Secondary · Reporting Duration: Every 12 weeks until end of study for at least 24 months from the start date of the study treatment
317 Total Participants · 4 Treatment Groups
Primary Treatment: NIR178 · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: